Apyx Medical Corporation (APYX) Stock Competitors & Peer Comparison
See (APYX) competitors and their performances in Stock Market.
Peer Comparison Table: Medical - Devices Industry
Detailed financial metrics including price, market cap, P/E ratio, and more.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| APYX | $4.29 | +13.19% | 179.6M | -19.50 | -$0.22 | N/A |
| BSX-PA | $122.18 | +2.37% | 175.4B | 230.53 | $0.53 | N/A |
| ABT | $90.78 | +4.36% | 158B | 25.41 | $3.57 | +2.71% |
| ISRG | $418.82 | +2.83% | 148.4B | 50.78 | $8.25 | N/A |
| SYK | $301.21 | +2.11% | 115.4B | 34.81 | $8.65 | +1.15% |
| MDT | $81.93 | +5.11% | 105.2B | 21.97 | $3.73 | +3.49% |
| BSX | $48.85 | +2.43% | 72.6B | 20.43 | $2.39 | N/A |
| BRKRP | $460.67 | -0.63% | 67.4B | N/A | N/A | +0.33% |
| EW | $87.45 | +1.69% | 50.3B | 47.26 | $1.85 | N/A |
| RMD | $194.32 | +4.22% | 28.2B | 18.74 | $10.37 | +1.25% |
Stock Comparison
APYX vs BSX-PA Comparison June 2026
APYX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, APYX stands at 179.6M. In comparison, BSX-PA has a market cap of 175.4B. Regarding current trading prices, APYX is priced at $4.29, while BSX-PA trades at $122.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
APYX currently has a P/E ratio of -19.50, whereas BSX-PA's P/E ratio is 230.53. In terms of profitability, APYX's ROE is -0.91%, compared to BSX-PA's ROE of +0.15%. Regarding short-term risk, APYX is more volatile compared to BSX-PA. This indicates potentially higher risk in terms of short-term price fluctuations for APYX.Check BSX-PA's competition here
APYX vs ABT Comparison June 2026
APYX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, APYX stands at 179.6M. In comparison, ABT has a market cap of 158B. Regarding current trading prices, APYX is priced at $4.29, while ABT trades at $90.78.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
APYX currently has a P/E ratio of -19.50, whereas ABT's P/E ratio is 25.41. In terms of profitability, APYX's ROE is -0.91%, compared to ABT's ROE of +0.12%. Regarding short-term risk, APYX is more volatile compared to ABT. This indicates potentially higher risk in terms of short-term price fluctuations for APYX.Check ABT's competition here
APYX vs ISRG Comparison June 2026
APYX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, APYX stands at 179.6M. In comparison, ISRG has a market cap of 148.4B. Regarding current trading prices, APYX is priced at $4.29, while ISRG trades at $418.82.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
APYX currently has a P/E ratio of -19.50, whereas ISRG's P/E ratio is 50.78. In terms of profitability, APYX's ROE is -0.91%, compared to ISRG's ROE of +0.17%. Regarding short-term risk, APYX is more volatile compared to ISRG. This indicates potentially higher risk in terms of short-term price fluctuations for APYX.Check ISRG's competition here
APYX vs SYK Comparison June 2026
APYX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, APYX stands at 179.6M. In comparison, SYK has a market cap of 115.4B. Regarding current trading prices, APYX is priced at $4.29, while SYK trades at $301.21.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
APYX currently has a P/E ratio of -19.50, whereas SYK's P/E ratio is 34.81. In terms of profitability, APYX's ROE is -0.91%, compared to SYK's ROE of +0.15%. Regarding short-term risk, APYX is more volatile compared to SYK. This indicates potentially higher risk in terms of short-term price fluctuations for APYX.Check SYK's competition here
APYX vs MDT Comparison June 2026
APYX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, APYX stands at 179.6M. In comparison, MDT has a market cap of 105.2B. Regarding current trading prices, APYX is priced at $4.29, while MDT trades at $81.93.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
APYX currently has a P/E ratio of -19.50, whereas MDT's P/E ratio is 21.97. In terms of profitability, APYX's ROE is -0.91%, compared to MDT's ROE of +0.10%. Regarding short-term risk, APYX is more volatile compared to MDT. This indicates potentially higher risk in terms of short-term price fluctuations for APYX.Check MDT's competition here
APYX vs BSX Comparison June 2026
APYX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, APYX stands at 179.6M. In comparison, BSX has a market cap of 72.6B. Regarding current trading prices, APYX is priced at $4.29, while BSX trades at $48.85.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
APYX currently has a P/E ratio of -19.50, whereas BSX's P/E ratio is 20.43. In terms of profitability, APYX's ROE is -0.91%, compared to BSX's ROE of +0.15%. Regarding short-term risk, APYX is more volatile compared to BSX. This indicates potentially higher risk in terms of short-term price fluctuations for APYX.Check BSX's competition here
APYX vs BRKRP Comparison June 2026
APYX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, APYX stands at 179.6M. In comparison, BRKRP has a market cap of 67.4B. Regarding current trading prices, APYX is priced at $4.29, while BRKRP trades at $460.67.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
APYX currently has a P/E ratio of -19.50, whereas BRKRP's P/E ratio is N/A. In terms of profitability, APYX's ROE is -0.91%, compared to BRKRP's ROE of -0.01%. Regarding short-term risk, APYX is more volatile compared to BRKRP. This indicates potentially higher risk in terms of short-term price fluctuations for APYX.Check BRKRP's competition here
APYX vs EW Comparison June 2026
APYX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, APYX stands at 179.6M. In comparison, EW has a market cap of 50.3B. Regarding current trading prices, APYX is priced at $4.29, while EW trades at $87.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
APYX currently has a P/E ratio of -19.50, whereas EW's P/E ratio is 47.26. In terms of profitability, APYX's ROE is -0.91%, compared to EW's ROE of +0.11%. Regarding short-term risk, APYX is more volatile compared to EW. This indicates potentially higher risk in terms of short-term price fluctuations for APYX.Check EW's competition here
APYX vs RMD Comparison June 2026
APYX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, APYX stands at 179.6M. In comparison, RMD has a market cap of 28.2B. Regarding current trading prices, APYX is priced at $4.29, while RMD trades at $194.32.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
APYX currently has a P/E ratio of -19.50, whereas RMD's P/E ratio is 18.74. In terms of profitability, APYX's ROE is -0.91%, compared to RMD's ROE of +0.24%. Regarding short-term risk, APYX is more volatile compared to RMD. This indicates potentially higher risk in terms of short-term price fluctuations for APYX.Check RMD's competition here
APYX vs DXCM Comparison June 2026
APYX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, APYX stands at 179.6M. In comparison, DXCM has a market cap of 28B. Regarding current trading prices, APYX is priced at $4.29, while DXCM trades at $72.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
APYX currently has a P/E ratio of -19.50, whereas DXCM's P/E ratio is 31.15. In terms of profitability, APYX's ROE is -0.91%, compared to DXCM's ROE of +0.34%. Regarding short-term risk, APYX is more volatile compared to DXCM. This indicates potentially higher risk in terms of short-term price fluctuations for APYX.Check DXCM's competition here
APYX vs PHG Comparison June 2026
APYX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, APYX stands at 179.6M. In comparison, PHG has a market cap of 25.3B. Regarding current trading prices, APYX is priced at $4.29, while PHG trades at $25.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
APYX currently has a P/E ratio of -19.50, whereas PHG's P/E ratio is 22.40. In terms of profitability, APYX's ROE is -0.91%, compared to PHG's ROE of +0.09%. Regarding short-term risk, APYX is more volatile compared to PHG. This indicates potentially higher risk in terms of short-term price fluctuations for APYX.Check PHG's competition here
APYX vs STE Comparison June 2026
APYX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, APYX stands at 179.6M. In comparison, STE has a market cap of 20.7B. Regarding current trading prices, APYX is priced at $4.29, while STE trades at $212.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
APYX currently has a P/E ratio of -19.50, whereas STE's P/E ratio is 26.76. In terms of profitability, APYX's ROE is -0.91%, compared to STE's ROE of +0.11%. Regarding short-term risk, APYX is more volatile compared to STE. This indicates potentially higher risk in terms of short-term price fluctuations for APYX.Check STE's competition here
APYX vs ABMD Comparison June 2026
APYX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, APYX stands at 179.6M. In comparison, ABMD has a market cap of 17.2B. Regarding current trading prices, APYX is priced at $4.29, while ABMD trades at $381.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
APYX currently has a P/E ratio of -19.50, whereas ABMD's P/E ratio is 65.36. In terms of profitability, APYX's ROE is -0.91%, compared to ABMD's ROE of +0.10%. Regarding short-term risk, APYX is more volatile compared to ABMD. This indicates potentially higher risk in terms of short-term price fluctuations for APYX.Check ABMD's competition here
APYX vs ZBH Comparison June 2026
APYX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, APYX stands at 179.6M. In comparison, ZBH has a market cap of 16.8B. Regarding current trading prices, APYX is priced at $4.29, while ZBH trades at $86.69.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
APYX currently has a P/E ratio of -19.50, whereas ZBH's P/E ratio is 22.46. In terms of profitability, APYX's ROE is -0.91%, compared to ZBH's ROE of +0.06%. Regarding short-term risk, APYX is more volatile compared to ZBH. This indicates potentially higher risk in terms of short-term price fluctuations for APYX.Check ZBH's competition here
APYX vs SNN Comparison June 2026
APYX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, APYX stands at 179.6M. In comparison, SNN has a market cap of 13.1B. Regarding current trading prices, APYX is priced at $4.29, while SNN trades at $30.85.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
APYX currently has a P/E ratio of -19.50, whereas SNN's P/E ratio is 21.57. In terms of profitability, APYX's ROE is -0.91%, compared to SNN's ROE of +0.12%. Regarding short-term risk, APYX is more volatile compared to SNN. This indicates potentially higher risk in terms of short-term price fluctuations for APYX.Check SNN's competition here
APYX vs PEN Comparison June 2026
APYX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, APYX stands at 179.6M. In comparison, PEN has a market cap of 12.6B. Regarding current trading prices, APYX is priced at $4.29, while PEN trades at $320.63.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
APYX currently has a P/E ratio of -19.50, whereas PEN's P/E ratio is 74.06. In terms of profitability, APYX's ROE is -0.91%, compared to PEN's ROE of +0.12%. Regarding short-term risk, APYX is more volatile compared to PEN. This indicates potentially higher risk in terms of short-term price fluctuations for APYX.Check PEN's competition here
APYX vs SWAV Comparison June 2026
APYX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, APYX stands at 179.6M. In comparison, SWAV has a market cap of 12.6B. Regarding current trading prices, APYX is priced at $4.29, while SWAV trades at $334.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
APYX currently has a P/E ratio of -19.50, whereas SWAV's P/E ratio is 78.76. In terms of profitability, APYX's ROE is -0.91%, compared to SWAV's ROE of +0.25%. Regarding short-term risk, APYX is more volatile compared to SWAV. This indicates potentially higher risk in terms of short-term price fluctuations for APYX.Check SWAV's competition here
APYX vs ALGN Comparison June 2026
APYX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, APYX stands at 179.6M. In comparison, ALGN has a market cap of 12.1B. Regarding current trading prices, APYX is priced at $4.29, while ALGN trades at $168.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
APYX currently has a P/E ratio of -19.50, whereas ALGN's P/E ratio is 28.33. In terms of profitability, APYX's ROE is -0.91%, compared to ALGN's ROE of +0.11%. Regarding short-term risk, APYX is more volatile compared to ALGN. This indicates potentially higher risk in terms of short-term price fluctuations for APYX.Check ALGN's competition here
APYX vs GMED Comparison June 2026
APYX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, APYX stands at 179.6M. In comparison, GMED has a market cap of 10.8B. Regarding current trading prices, APYX is priced at $4.29, while GMED trades at $80.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
APYX currently has a P/E ratio of -19.50, whereas GMED's P/E ratio is 18.69. In terms of profitability, APYX's ROE is -0.91%, compared to GMED's ROE of +0.13%. Regarding short-term risk, APYX is more volatile compared to GMED. This indicates potentially higher risk in terms of short-term price fluctuations for APYX.Check GMED's competition here
APYX vs PODD Comparison June 2026
APYX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, APYX stands at 179.6M. In comparison, PODD has a market cap of 10.1B. Regarding current trading prices, APYX is priced at $4.29, while PODD trades at $146.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
APYX currently has a P/E ratio of -19.50, whereas PODD's P/E ratio is 34.29. In terms of profitability, APYX's ROE is -0.91%, compared to PODD's ROE of +0.21%. Regarding short-term risk, APYX is more volatile compared to PODD. This indicates potentially higher risk in terms of short-term price fluctuations for APYX.Check PODD's competition here
APYX vs MASI Comparison June 2026
APYX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, APYX stands at 179.6M. In comparison, MASI has a market cap of 9.4B. Regarding current trading prices, APYX is priced at $4.29, while MASI trades at $178.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
APYX currently has a P/E ratio of -19.50, whereas MASI's P/E ratio is 44.28. In terms of profitability, APYX's ROE is -0.91%, compared to MASI's ROE of +0.09%. Regarding short-term risk, APYX is more volatile compared to MASI. This indicates potentially higher risk in terms of short-term price fluctuations for APYX.Check MASI's competition here
APYX vs BRKR Comparison June 2026
APYX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, APYX stands at 179.6M. In comparison, BRKR has a market cap of 9.1B. Regarding current trading prices, APYX is priced at $4.29, while BRKR trades at $59.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
APYX currently has a P/E ratio of -19.50, whereas BRKR's P/E ratio is -249.83. In terms of profitability, APYX's ROE is -0.91%, compared to BRKR's ROE of -0.01%. Regarding short-term risk, APYX is more volatile compared to BRKR. This indicates potentially higher risk in terms of short-term price fluctuations for APYX.Check BRKR's competition here
APYX vs BIO-B Comparison June 2026
APYX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, APYX stands at 179.6M. In comparison, BIO-B has a market cap of 8.7B. Regarding current trading prices, APYX is priced at $4.29, while BIO-B trades at $321.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
APYX currently has a P/E ratio of -19.50, whereas BIO-B's P/E ratio is 53.40. In terms of profitability, APYX's ROE is -0.91%, compared to BIO-B's ROE of +0.02%. Regarding short-term risk, APYX is more volatile compared to BIO-B. This indicates potentially higher risk in terms of short-term price fluctuations for APYX.Check BIO-B's competition here
APYX vs BIO Comparison June 2026
APYX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, APYX stands at 179.6M. In comparison, BIO has a market cap of 8.3B. Regarding current trading prices, APYX is priced at $4.29, while BIO trades at $307.47.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
APYX currently has a P/E ratio of -19.50, whereas BIO's P/E ratio is 51.06. In terms of profitability, APYX's ROE is -0.91%, compared to BIO's ROE of +0.02%. Regarding short-term risk, APYX is more volatile compared to BIO. This indicates potentially higher risk in terms of short-term price fluctuations for APYX.Check BIO's competition here
APYX vs GKOS Comparison June 2026
APYX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, APYX stands at 179.6M. In comparison, GKOS has a market cap of 7.1B. Regarding current trading prices, APYX is priced at $4.29, while GKOS trades at $121.69.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
APYX currently has a P/E ratio of -19.50, whereas GKOS's P/E ratio is -36.87. In terms of profitability, APYX's ROE is -0.91%, compared to GKOS's ROE of -0.26%. Regarding short-term risk, APYX is more volatile compared to GKOS. This indicates potentially higher risk in terms of short-term price fluctuations for APYX.Check GKOS's competition here
APYX vs NARI Comparison June 2026
APYX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, APYX stands at 179.6M. In comparison, NARI has a market cap of 4.7B. Regarding current trading prices, APYX is priced at $4.29, while NARI trades at $79.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
APYX currently has a P/E ratio of -19.50, whereas NARI's P/E ratio is -59.24. In terms of profitability, APYX's ROE is -0.91%, compared to NARI's ROE of -0.00%. Regarding short-term risk, APYX is more volatile compared to NARI. This indicates potentially higher risk in terms of short-term price fluctuations for APYX.Check NARI's competition here
APYX vs LIVN Comparison June 2026
APYX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, APYX stands at 179.6M. In comparison, LIVN has a market cap of 4B. Regarding current trading prices, APYX is priced at $4.29, while LIVN trades at $73.72.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
APYX currently has a P/E ratio of -19.50, whereas LIVN's P/E ratio is 37.61. In terms of profitability, APYX's ROE is -0.91%, compared to LIVN's ROE of +0.09%. Regarding short-term risk, APYX is more volatile compared to LIVN. This indicates potentially higher risk in terms of short-term price fluctuations for APYX.Check LIVN's competition here
APYX vs AXNX Comparison June 2026
APYX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, APYX stands at 179.6M. In comparison, AXNX has a market cap of 3.6B. Regarding current trading prices, APYX is priced at $4.29, while AXNX trades at $70.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
APYX currently has a P/E ratio of -19.50, whereas AXNX's P/E ratio is -709.80. In terms of profitability, APYX's ROE is -0.91%, compared to AXNX's ROE of -0.01%. Regarding short-term risk, APYX is more volatile compared to AXNX. This indicates potentially higher risk in terms of short-term price fluctuations for APYX.Check AXNX's competition here
APYX vs IRTC Comparison June 2026
APYX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, APYX stands at 179.6M. In comparison, IRTC has a market cap of 3.5B. Regarding current trading prices, APYX is priced at $4.29, while IRTC trades at $107.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
APYX currently has a P/E ratio of -19.50, whereas IRTC's P/E ratio is -126.29. In terms of profitability, APYX's ROE is -0.91%, compared to IRTC's ROE of -0.21%. Regarding short-term risk, APYX is more volatile compared to IRTC. This indicates potentially higher risk in terms of short-term price fluctuations for APYX.Check IRTC's competition here
APYX vs ITGR Comparison June 2026
APYX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, APYX stands at 179.6M. In comparison, ITGR has a market cap of 3.1B. Regarding current trading prices, APYX is priced at $4.29, while ITGR trades at $92.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
APYX currently has a P/E ratio of -19.50, whereas ITGR's P/E ratio is 23.01. In terms of profitability, APYX's ROE is -0.91%, compared to ITGR's ROE of +0.08%. Regarding short-term risk, APYX is more volatile compared to ITGR. This indicates potentially higher risk in terms of short-term price fluctuations for APYX.Check ITGR's competition here
APYX vs TMDX Comparison June 2026
APYX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, APYX stands at 179.6M. In comparison, TMDX has a market cap of 2.5B. Regarding current trading prices, APYX is priced at $4.29, while TMDX trades at $71.37.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
APYX currently has a P/E ratio of -19.50, whereas TMDX's P/E ratio is 16.33. In terms of profitability, APYX's ROE is -0.91%, compared to TMDX's ROE of +0.42%. Regarding short-term risk, APYX is more volatile compared to TMDX. This indicates potentially higher risk in terms of short-term price fluctuations for APYX.Check TMDX's competition here
APYX vs AXGN Comparison June 2026
APYX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, APYX stands at 179.6M. In comparison, AXGN has a market cap of 2.3B. Regarding current trading prices, APYX is priced at $4.29, while AXGN trades at $42.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
APYX currently has a P/E ratio of -19.50, whereas AXGN's P/E ratio is -66.23. In terms of profitability, APYX's ROE is -0.91%, compared to AXGN's ROE of -0.21%. Regarding short-term risk, APYX is more volatile compared to AXGN. This indicates potentially higher risk in terms of short-term price fluctuations for APYX.Check AXGN's competition here
APYX vs ESTA Comparison June 2026
APYX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, APYX stands at 179.6M. In comparison, ESTA has a market cap of 2.3B. Regarding current trading prices, APYX is priced at $4.29, while ESTA trades at $76.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
APYX currently has a P/E ratio of -19.50, whereas ESTA's P/E ratio is -52.03. In terms of profitability, APYX's ROE is -0.91%, compared to ESTA's ROE of -2.26%. Regarding short-term risk, APYX is more volatile compared to ESTA. This indicates potentially higher risk in terms of short-term price fluctuations for APYX.Check ESTA's competition here
APYX vs NUVA Comparison June 2026
APYX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, APYX stands at 179.6M. In comparison, NUVA has a market cap of 2.1B. Regarding current trading prices, APYX is priced at $4.29, while NUVA trades at $39.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
APYX currently has a P/E ratio of -19.50, whereas NUVA's P/E ratio is 75.00. In terms of profitability, APYX's ROE is -0.91%, compared to NUVA's ROE of +0.05%. Regarding short-term risk, APYX is more volatile compared to NUVA. This indicates potentially higher risk in terms of short-term price fluctuations for APYX.Check NUVA's competition here
APYX vs UFPT Comparison June 2026
APYX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, APYX stands at 179.6M. In comparison, UFPT has a market cap of 1.7B. Regarding current trading prices, APYX is priced at $4.29, while UFPT trades at $224.51.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
APYX currently has a P/E ratio of -19.50, whereas UFPT's P/E ratio is 25.54. In terms of profitability, APYX's ROE is -0.91%, compared to UFPT's ROE of +0.17%. Regarding short-term risk, APYX is more volatile compared to UFPT. This indicates potentially higher risk in terms of short-term price fluctuations for APYX.Check UFPT's competition here
APYX vs PRCT Comparison June 2026
APYX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, APYX stands at 179.6M. In comparison, PRCT has a market cap of 1.5B. Regarding current trading prices, APYX is priced at $4.29, while PRCT trades at $27.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
APYX currently has a P/E ratio of -19.50, whereas PRCT's P/E ratio is -14.75. In terms of profitability, APYX's ROE is -0.91%, compared to PRCT's ROE of -0.28%. Regarding short-term risk, APYX is more volatile compared to PRCT. This indicates potentially higher risk in terms of short-term price fluctuations for APYX.Check PRCT's competition here
APYX vs IART Comparison June 2026
APYX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, APYX stands at 179.6M. In comparison, IART has a market cap of 1.4B. Regarding current trading prices, APYX is priced at $4.29, while IART trades at $17.56.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
APYX currently has a P/E ratio of -19.50, whereas IART's P/E ratio is -2.71. In terms of profitability, APYX's ROE is -0.91%, compared to IART's ROE of -0.48%. Regarding short-term risk, APYX is more volatile compared to IART. This indicates potentially higher risk in terms of short-term price fluctuations for APYX.Check IART's competition here
APYX vs BFLY Comparison June 2026
APYX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, APYX stands at 179.6M. In comparison, BFLY has a market cap of 1.4B. Regarding current trading prices, APYX is priced at $4.29, while BFLY trades at $5.19.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
APYX currently has a P/E ratio of -19.50, whereas BFLY's P/E ratio is -17.30. In terms of profitability, APYX's ROE is -0.91%, compared to BFLY's ROE of -0.37%. Regarding short-term risk, APYX is less volatile compared to BFLY. This indicates potentially lower risk in terms of short-term price fluctuations for APYX.Check BFLY's competition here
APYX vs TNDM Comparison June 2026
APYX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, APYX stands at 179.6M. In comparison, TNDM has a market cap of 1.3B. Regarding current trading prices, APYX is priced at $4.29, while TNDM trades at $19.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
APYX currently has a P/E ratio of -19.50, whereas TNDM's P/E ratio is -14.19. In terms of profitability, APYX's ROE is -0.91%, compared to TNDM's ROE of -0.68%. Regarding short-term risk, APYX is more volatile compared to TNDM. This indicates potentially higher risk in terms of short-term price fluctuations for APYX.Check TNDM's competition here
APYX vs AHCO Comparison June 2026
APYX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, APYX stands at 179.6M. In comparison, AHCO has a market cap of 1.3B. Regarding current trading prices, APYX is priced at $4.29, while AHCO trades at $9.73.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
APYX currently has a P/E ratio of -19.50, whereas AHCO's P/E ratio is -16.47. In terms of profitability, APYX's ROE is -0.91%, compared to AHCO's ROE of -0.05%. Regarding short-term risk, APYX is more volatile compared to AHCO. This indicates potentially higher risk in terms of short-term price fluctuations for APYX.Check AHCO's competition here
APYX vs ENOV Comparison June 2026
APYX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, APYX stands at 179.6M. In comparison, ENOV has a market cap of 1.3B. Regarding current trading prices, APYX is priced at $4.29, while ENOV trades at $22.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
APYX currently has a P/E ratio of -19.50, whereas ENOV's P/E ratio is -1.15. In terms of profitability, APYX's ROE is -0.91%, compared to ENOV's ROE of -0.60%. Regarding short-term risk, APYX is more volatile compared to ENOV. This indicates potentially higher risk in terms of short-term price fluctuations for APYX.Check ENOV's competition here
APYX vs HSKA Comparison June 2026
APYX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, APYX stands at 179.6M. In comparison, HSKA has a market cap of 1.3B. Regarding current trading prices, APYX is priced at $4.29, while HSKA trades at $119.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
APYX currently has a P/E ratio of -19.50, whereas HSKA's P/E ratio is -62.49. In terms of profitability, APYX's ROE is -0.91%, compared to HSKA's ROE of -0.04%. Regarding short-term risk, APYX is more volatile compared to HSKA. This indicates potentially higher risk in terms of short-term price fluctuations for APYX.Check HSKA's competition here
APYX vs ATEC Comparison June 2026
APYX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, APYX stands at 179.6M. In comparison, ATEC has a market cap of 1.2B. Regarding current trading prices, APYX is priced at $4.29, while ATEC trades at $7.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
APYX currently has a P/E ratio of -19.50, whereas ATEC's P/E ratio is -9.54. In terms of profitability, APYX's ROE is -0.91%, compared to ATEC's ROE of -4.43%. Regarding short-term risk, APYX is more volatile compared to ATEC. This indicates potentially higher risk in terms of short-term price fluctuations for APYX.Check ATEC's competition here
APYX vs INSP Comparison June 2026
APYX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, APYX stands at 179.6M. In comparison, INSP has a market cap of 1.2B. Regarding current trading prices, APYX is priced at $4.29, while INSP trades at $42.19.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
APYX currently has a P/E ratio of -19.50, whereas INSP's P/E ratio is 9.58. In terms of profitability, APYX's ROE is -0.91%, compared to INSP's ROE of +0.18%. Regarding short-term risk, APYX is more volatile compared to INSP. This indicates potentially higher risk in terms of short-term price fluctuations for APYX.Check INSP's competition here
APYX vs IRMD Comparison June 2026
APYX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, APYX stands at 179.6M. In comparison, IRMD has a market cap of 1.2B. Regarding current trading prices, APYX is priced at $4.29, while IRMD trades at $93.57.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
APYX currently has a P/E ratio of -19.50, whereas IRMD's P/E ratio is 51.13. In terms of profitability, APYX's ROE is -0.91%, compared to IRMD's ROE of +0.24%. Regarding short-term risk, APYX is more volatile compared to IRMD. This indicates potentially higher risk in terms of short-term price fluctuations for APYX.Check IRMD's competition here
APYX vs AVNS Comparison June 2026
APYX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, APYX stands at 179.6M. In comparison, AVNS has a market cap of 1.2B. Regarding current trading prices, APYX is priced at $4.29, while AVNS trades at $25.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
APYX currently has a P/E ratio of -19.50, whereas AVNS's P/E ratio is -15.62. In terms of profitability, APYX's ROE is -0.91%, compared to AVNS's ROE of -0.09%. Regarding short-term risk, APYX is more volatile compared to AVNS. This indicates potentially higher risk in terms of short-term price fluctuations for APYX.Check AVNS's competition here
APYX vs SILK Comparison June 2026
APYX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, APYX stands at 179.6M. In comparison, SILK has a market cap of 1.1B. Regarding current trading prices, APYX is priced at $4.29, while SILK trades at $27.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
APYX currently has a P/E ratio of -19.50, whereas SILK's P/E ratio is -18.96. In terms of profitability, APYX's ROE is -0.91%, compared to SILK's ROE of -0.35%. Regarding short-term risk, APYX is more volatile compared to SILK. This indicates potentially higher risk in terms of short-term price fluctuations for APYX.Check SILK's competition here
APYX vs FNA Comparison June 2026
APYX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, APYX stands at 179.6M. In comparison, FNA has a market cap of 1.1B. Regarding current trading prices, APYX is priced at $4.29, while FNA trades at $13.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
APYX currently has a P/E ratio of -19.50, whereas FNA's P/E ratio is -19.83. In terms of profitability, APYX's ROE is -0.91%, compared to FNA's ROE of -0.35%. Regarding short-term risk, APYX is more volatile compared to FNA. This indicates potentially higher risk in terms of short-term price fluctuations for APYX.Check FNA's competition here
APYX vs CNMD Comparison June 2026
APYX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, APYX stands at 179.6M. In comparison, CNMD has a market cap of 1.1B. Regarding current trading prices, APYX is priced at $4.29, while CNMD trades at $35.13.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
APYX currently has a P/E ratio of -19.50, whereas CNMD's P/E ratio is 19.84. In terms of profitability, APYX's ROE is -0.91%, compared to CNMD's ROE of +0.05%. Regarding short-term risk, APYX is more volatile compared to CNMD. This indicates potentially higher risk in terms of short-term price fluctuations for APYX.Check CNMD's competition here
APYX vs AORT Comparison June 2026
APYX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, APYX stands at 179.6M. In comparison, AORT has a market cap of 1B. Regarding current trading prices, APYX is priced at $4.29, while AORT trades at $20.84.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
APYX currently has a P/E ratio of -19.50, whereas AORT's P/E ratio is 83.32. In terms of profitability, APYX's ROE is -0.91%, compared to AORT's ROE of +0.03%. Regarding short-term risk, APYX is more volatile compared to AORT. This indicates potentially higher risk in terms of short-term price fluctuations for APYX.Check AORT's competition here
APYX vs CSII Comparison June 2026
APYX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, APYX stands at 179.6M. In comparison, CSII has a market cap of 844M. Regarding current trading prices, APYX is priced at $4.29, while CSII trades at $20.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
APYX currently has a P/E ratio of -19.50, whereas CSII's P/E ratio is -20.83. In terms of profitability, APYX's ROE is -0.91%, compared to CSII's ROE of -0.14%. Regarding short-term risk, APYX is more volatile compared to CSII. This indicates potentially higher risk in terms of short-term price fluctuations for APYX.Check CSII's competition here
APYX vs INMD Comparison June 2026
APYX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, APYX stands at 179.6M. In comparison, INMD has a market cap of 828.2M. Regarding current trading prices, APYX is priced at $4.29, while INMD trades at $13.62.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
APYX currently has a P/E ratio of -19.50, whereas INMD's P/E ratio is 10.09. In terms of profitability, APYX's ROE is -0.91%, compared to INMD's ROE of +0.13%. Regarding short-term risk, APYX is more volatile compared to INMD. This indicates potentially higher risk in terms of short-term price fluctuations for APYX.Check INMD's competition here
APYX vs LMRI Comparison June 2026
APYX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, APYX stands at 179.6M. In comparison, LMRI has a market cap of 791.7M. Regarding current trading prices, APYX is priced at $4.29, while LMRI trades at $8.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
APYX currently has a P/E ratio of -19.50, whereas LMRI's P/E ratio is -21.13. In terms of profitability, APYX's ROE is -0.91%, compared to LMRI's ROE of -0.15%. Regarding short-term risk, APYX is more volatile compared to LMRI. This indicates potentially higher risk in terms of short-term price fluctuations for APYX.Check LMRI's competition here
APYX vs SSII Comparison June 2026
APYX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, APYX stands at 179.6M. In comparison, SSII has a market cap of 768.5M. Regarding current trading prices, APYX is priced at $4.29, while SSII trades at $3.84.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
APYX currently has a P/E ratio of -19.50, whereas SSII's P/E ratio is -76.80. In terms of profitability, APYX's ROE is -0.91%, compared to SSII's ROE of -0.23%. Regarding short-term risk, APYX is more volatile compared to SSII. This indicates potentially higher risk in terms of short-term price fluctuations for APYX.Check SSII's competition here
APYX vs CRY Comparison June 2026
APYX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, APYX stands at 179.6M. In comparison, CRY has a market cap of 725.1M. Regarding current trading prices, APYX is priced at $4.29, while CRY trades at $17.88.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
APYX currently has a P/E ratio of -19.50, whereas CRY's P/E ratio is 425.71. In terms of profitability, APYX's ROE is -0.91%, compared to CRY's ROE of +0.03%. Regarding short-term risk, APYX is more volatile compared to CRY. This indicates potentially higher risk in terms of short-term price fluctuations for APYX.Check CRY's competition here
APYX vs CBLL Comparison June 2026
APYX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, APYX stands at 179.6M. In comparison, CBLL has a market cap of 711.4M. Regarding current trading prices, APYX is priced at $4.29, while CBLL trades at $18.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
APYX currently has a P/E ratio of -19.50, whereas CBLL's P/E ratio is -11.57. In terms of profitability, APYX's ROE is -0.91%, compared to CBLL's ROE of -0.38%. Regarding short-term risk, APYX is more volatile compared to CBLL. This indicates potentially higher risk in terms of short-term price fluctuations for APYX.Check CBLL's competition here
APYX vs SIBN Comparison June 2026
APYX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, APYX stands at 179.6M. In comparison, SIBN has a market cap of 659.9M. Regarding current trading prices, APYX is priced at $4.29, while SIBN trades at $14.88.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
APYX currently has a P/E ratio of -19.50, whereas SIBN's P/E ratio is -38.15. In terms of profitability, APYX's ROE is -0.91%, compared to SIBN's ROE of -0.10%. Regarding short-term risk, APYX is more volatile compared to SIBN. This indicates potentially higher risk in terms of short-term price fluctuations for APYX.Check SIBN's competition here
APYX vs SRDX Comparison June 2026
APYX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, APYX stands at 179.6M. In comparison, SRDX has a market cap of 614.5M. Regarding current trading prices, APYX is priced at $4.29, while SRDX trades at $42.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
APYX currently has a P/E ratio of -19.50, whereas SRDX's P/E ratio is -34.66. In terms of profitability, APYX's ROE is -0.91%, compared to SRDX's ROE of -0.13%. Regarding short-term risk, APYX is more volatile compared to SRDX. This indicates potentially higher risk in terms of short-term price fluctuations for APYX.Check SRDX's competition here
APYX vs BVS Comparison June 2026
APYX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, APYX stands at 179.6M. In comparison, BVS has a market cap of 589.4M. Regarding current trading prices, APYX is priced at $4.29, while BVS trades at $8.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
APYX currently has a P/E ratio of -19.50, whereas BVS's P/E ratio is 21.22. In terms of profitability, APYX's ROE is -0.91%, compared to BVS's ROE of +0.16%. Regarding short-term risk, APYX is more volatile compared to BVS. This indicates potentially higher risk in terms of short-term price fluctuations for APYX.Check BVS's competition here
APYX vs APEN Comparison June 2026
APYX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, APYX stands at 179.6M. In comparison, APEN has a market cap of 579.7M. Regarding current trading prices, APYX is priced at $4.29, while APEN trades at $10.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
APYX currently has a P/E ratio of -19.50, whereas APEN's P/E ratio is -9.43. In terms of profitability, APYX's ROE is -0.91%, compared to APEN's ROE of -0.85%. Regarding short-term risk, APYX is more volatile compared to APEN. This indicates potentially higher risk in terms of short-term price fluctuations for APYX.Check APEN's competition here
APYX vs TCMD Comparison June 2026
APYX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, APYX stands at 179.6M. In comparison, TCMD has a market cap of 567.7M. Regarding current trading prices, APYX is priced at $4.29, while TCMD trades at $25.17.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
APYX currently has a P/E ratio of -19.50, whereas TCMD's P/E ratio is 28.93. In terms of profitability, APYX's ROE is -0.91%, compared to TCMD's ROE of +0.10%. Regarding short-term risk, APYX is more volatile compared to TCMD. This indicates potentially higher risk in terms of short-term price fluctuations for APYX.Check TCMD's competition here
APYX vs BWAY Comparison June 2026
APYX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, APYX stands at 179.6M. In comparison, BWAY has a market cap of 559.7M. Regarding current trading prices, APYX is priced at $4.29, while BWAY trades at $14.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
APYX currently has a P/E ratio of -19.50, whereas BWAY's P/E ratio is 64.86. In terms of profitability, APYX's ROE is -0.91%, compared to BWAY's ROE of +0.12%. Regarding short-term risk, APYX is more volatile compared to BWAY. This indicates potentially higher risk in terms of short-term price fluctuations for APYX.Check BWAY's competition here
APYX vs CTKB Comparison June 2026
APYX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, APYX stands at 179.6M. In comparison, CTKB has a market cap of 559.2M. Regarding current trading prices, APYX is priced at $4.29, while CTKB trades at $4.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
APYX currently has a P/E ratio of -19.50, whereas CTKB's P/E ratio is -7.47. In terms of profitability, APYX's ROE is -0.91%, compared to CTKB's ROE of -0.21%. Regarding short-term risk, APYX is more volatile compared to CTKB. This indicates potentially higher risk in terms of short-term price fluctuations for APYX.Check CTKB's competition here
APYX vs CERS Comparison June 2026
APYX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, APYX stands at 179.6M. In comparison, CERS has a market cap of 559M. Regarding current trading prices, APYX is priced at $4.29, while CERS trades at $2.79.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
APYX currently has a P/E ratio of -19.50, whereas CERS's P/E ratio is -55.80. In terms of profitability, APYX's ROE is -0.91%, compared to CERS's ROE of -0.15%. Regarding short-term risk, APYX is more volatile compared to CERS. This indicates potentially higher risk in terms of short-term price fluctuations for APYX.Check CERS's competition here
APYX vs NPCE Comparison June 2026
APYX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, APYX stands at 179.6M. In comparison, NPCE has a market cap of 556.4M. Regarding current trading prices, APYX is priced at $4.29, while NPCE trades at $16.32.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
APYX currently has a P/E ratio of -19.50, whereas NPCE's P/E ratio is -25.11. In terms of profitability, APYX's ROE is -0.91%, compared to NPCE's ROE of -1.21%. Regarding short-term risk, APYX is more volatile compared to NPCE. This indicates potentially higher risk in terms of short-term price fluctuations for APYX.Check NPCE's competition here
APYX vs ZIMV Comparison June 2026
APYX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, APYX stands at 179.6M. In comparison, ZIMV has a market cap of 535.6M. Regarding current trading prices, APYX is priced at $4.29, while ZIMV trades at $18.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
APYX currently has a P/E ratio of -19.50, whereas ZIMV's P/E ratio is -27.52. In terms of profitability, APYX's ROE is -0.91%, compared to ZIMV's ROE of -0.04%. Regarding short-term risk, APYX is more volatile compared to ZIMV. This indicates potentially higher risk in terms of short-term price fluctuations for APYX.Check ZIMV's competition here
APYX vs PACB Comparison June 2026
APYX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, APYX stands at 179.6M. In comparison, PACB has a market cap of 506.3M. Regarding current trading prices, APYX is priced at $4.29, while PACB trades at $1.63.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
APYX currently has a P/E ratio of -19.50, whereas PACB's P/E ratio is -3.98. In terms of profitability, APYX's ROE is -0.91%, compared to PACB's ROE of -4.88%. Regarding short-term risk, APYX is more volatile compared to PACB. This indicates potentially higher risk in terms of short-term price fluctuations for APYX.Check PACB's competition here
APYX vs PMI Comparison June 2026
APYX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, APYX stands at 179.6M. In comparison, PMI has a market cap of 498.9M. Regarding current trading prices, APYX is priced at $4.29, while PMI trades at $0.32.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
APYX currently has a P/E ratio of -19.50, whereas PMI's P/E ratio is -0.42. In terms of profitability, APYX's ROE is -0.91%, compared to PMI's ROE of +4.99%. Regarding short-term risk, APYX is less volatile compared to PMI. This indicates potentially lower risk in terms of short-term price fluctuations for APYX.Check PMI's competition here
APYX vs LAB Comparison June 2026
APYX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, APYX stands at 179.6M. In comparison, LAB has a market cap of 488M. Regarding current trading prices, APYX is priced at $4.29, while LAB trades at $1.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
APYX currently has a P/E ratio of -19.50, whereas LAB's P/E ratio is -9.62. In terms of profitability, APYX's ROE is -0.91%, compared to LAB's ROE of -0.21%. Regarding short-term risk, APYX is more volatile compared to LAB. This indicates potentially higher risk in terms of short-term price fluctuations for APYX.Check LAB's competition here
APYX vs KIDS Comparison June 2026
APYX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, APYX stands at 179.6M. In comparison, KIDS has a market cap of 464.9M. Regarding current trading prices, APYX is priced at $4.29, while KIDS trades at $18.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
APYX currently has a P/E ratio of -19.50, whereas KIDS's P/E ratio is -10.77. In terms of profitability, APYX's ROE is -0.91%, compared to KIDS's ROE of -0.11%. Regarding short-term risk, APYX is more volatile compared to KIDS. This indicates potentially higher risk in terms of short-term price fluctuations for APYX.Check KIDS's competition here
APYX vs VREX Comparison June 2026
APYX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, APYX stands at 179.6M. In comparison, VREX has a market cap of 440.4M. Regarding current trading prices, APYX is priced at $4.29, while VREX trades at $10.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
APYX currently has a P/E ratio of -19.50, whereas VREX's P/E ratio is -5.23. In terms of profitability, APYX's ROE is -0.91%, compared to VREX's ROE of -0.18%. Regarding short-term risk, APYX is more volatile compared to VREX. This indicates potentially higher risk in terms of short-term price fluctuations for APYX.Check VREX's competition here
APYX vs CLPT Comparison June 2026
APYX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, APYX stands at 179.6M. In comparison, CLPT has a market cap of 429.5M. Regarding current trading prices, APYX is priced at $4.29, while CLPT trades at $14.32.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
APYX currently has a P/E ratio of -19.50, whereas CLPT's P/E ratio is -14.32. In terms of profitability, APYX's ROE is -0.91%, compared to CLPT's ROE of -1.41%. Regarding short-term risk, APYX is more volatile compared to CLPT. This indicates potentially higher risk in terms of short-term price fluctuations for APYX.Check CLPT's competition here
APYX vs OFIX Comparison June 2026
APYX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, APYX stands at 179.6M. In comparison, OFIX has a market cap of 416.7M. Regarding current trading prices, APYX is priced at $4.29, while OFIX trades at $10.34.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
APYX currently has a P/E ratio of -19.50, whereas OFIX's P/E ratio is -6.87. In terms of profitability, APYX's ROE is -0.91%, compared to OFIX's ROE of -0.13%. Regarding short-term risk, APYX is more volatile compared to OFIX. This indicates potentially higher risk in terms of short-term price fluctuations for APYX.Check OFIX's competition here
APYX vs VMD Comparison June 2026
APYX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, APYX stands at 179.6M. In comparison, VMD has a market cap of 377.2M. Regarding current trading prices, APYX is priced at $4.29, while VMD trades at $9.84.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
APYX currently has a P/E ratio of -19.50, whereas VMD's P/E ratio is 26.59. In terms of profitability, APYX's ROE is -0.91%, compared to VMD's ROE of +0.11%. Regarding short-term risk, APYX is more volatile compared to VMD. This indicates potentially higher risk in terms of short-term price fluctuations for APYX.Check VMD's competition here
APYX vs DCTH Comparison June 2026
APYX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, APYX stands at 179.6M. In comparison, DCTH has a market cap of 372.5M. Regarding current trading prices, APYX is priced at $4.29, while DCTH trades at $10.79.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
APYX currently has a P/E ratio of -19.50, whereas DCTH's P/E ratio is 1079.00. In terms of profitability, APYX's ROE is -0.91%, compared to DCTH's ROE of +0.01%. Regarding short-term risk, APYX is more volatile compared to DCTH. This indicates potentially higher risk in terms of short-term price fluctuations for APYX.Check DCTH's competition here
APYX vs AVR Comparison June 2026
APYX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, APYX stands at 179.6M. In comparison, AVR has a market cap of 355M. Regarding current trading prices, APYX is priced at $4.29, while AVR trades at $9.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
APYX currently has a P/E ratio of -19.50, whereas AVR's P/E ratio is -4.35. In terms of profitability, APYX's ROE is -0.91%, compared to AVR's ROE of -1.24%. Regarding short-term risk, APYX is more volatile compared to AVR. This indicates potentially higher risk in terms of short-term price fluctuations for APYX.Check AVR's competition here
APYX vs ICCM Comparison June 2026
APYX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, APYX stands at 179.6M. In comparison, ICCM has a market cap of 347.8M. Regarding current trading prices, APYX is priced at $4.29, while ICCM trades at $5.22.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
APYX currently has a P/E ratio of -19.50, whereas ICCM's P/E ratio is -21.54. In terms of profitability, APYX's ROE is -0.91%, compared to ICCM's ROE of -2.12%. Regarding short-term risk, APYX is less volatile compared to ICCM. This indicates potentially lower risk in terms of short-term price fluctuations for APYX.Check ICCM's competition here
APYX vs MASS Comparison June 2026
APYX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, APYX stands at 179.6M. In comparison, MASS has a market cap of 333.5M. Regarding current trading prices, APYX is priced at $4.29, while MASS trades at $8.82.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
APYX currently has a P/E ratio of -19.50, whereas MASS's P/E ratio is -9.09. In terms of profitability, APYX's ROE is -0.91%, compared to MASS's ROE of -0.26%. Regarding short-term risk, APYX is more volatile compared to MASS. This indicates potentially higher risk in terms of short-term price fluctuations for APYX.Check MASS's competition here
APYX vs SMLR Comparison June 2026
APYX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, APYX stands at 179.6M. In comparison, SMLR has a market cap of 310.7M. Regarding current trading prices, APYX is priced at $4.29, while SMLR trades at $20.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
APYX currently has a P/E ratio of -19.50, whereas SMLR's P/E ratio is 3.92. In terms of profitability, APYX's ROE is -0.91%, compared to SMLR's ROE of +0.16%. Regarding short-term risk, APYX is more volatile compared to SMLR. This indicates potentially higher risk in terms of short-term price fluctuations for APYX.Check SMLR's competition here
APYX vs ELMD Comparison June 2026
APYX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, APYX stands at 179.6M. In comparison, ELMD has a market cap of 305.3M. Regarding current trading prices, APYX is priced at $4.29, while ELMD trades at $36.72.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
APYX currently has a P/E ratio of -19.50, whereas ELMD's P/E ratio is 31.51. In terms of profitability, APYX's ROE is -0.91%, compared to ELMD's ROE of +0.22%. Regarding short-term risk, APYX is more volatile compared to ELMD. This indicates potentially higher risk in terms of short-term price fluctuations for APYX.Check ELMD's competition here
APYX vs SENS Comparison June 2026
APYX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, APYX stands at 179.6M. In comparison, SENS has a market cap of 292.8M. Regarding current trading prices, APYX is priced at $4.29, while SENS trades at $7.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
APYX currently has a P/E ratio of -19.50, whereas SENS's P/E ratio is -3.56. In terms of profitability, APYX's ROE is -0.91%, compared to SENS's ROE of -1.30%. Regarding short-term risk, APYX is more volatile compared to SENS. This indicates potentially higher risk in terms of short-term price fluctuations for APYX.Check SENS's competition here
APYX vs CATX Comparison June 2026
APYX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, APYX stands at 179.6M. In comparison, CATX has a market cap of 250.3M. Regarding current trading prices, APYX is priced at $4.29, while CATX trades at $3.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
APYX currently has a P/E ratio of -19.50, whereas CATX's P/E ratio is -2.30. In terms of profitability, APYX's ROE is -0.91%, compared to CATX's ROE of -0.42%. Regarding short-term risk, APYX is less volatile compared to CATX. This indicates potentially lower risk in terms of short-term price fluctuations for APYX.Check CATX's competition here
APYX vs SGHT Comparison June 2026
APYX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, APYX stands at 179.6M. In comparison, SGHT has a market cap of 250.3M. Regarding current trading prices, APYX is priced at $4.29, while SGHT trades at $4.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
APYX currently has a P/E ratio of -19.50, whereas SGHT's P/E ratio is -6.57. In terms of profitability, APYX's ROE is -0.91%, compared to SGHT's ROE of -0.59%. Regarding short-term risk, APYX is more volatile compared to SGHT. This indicates potentially higher risk in terms of short-term price fluctuations for APYX.Check SGHT's competition here
APYX vs MGRM Comparison June 2026
APYX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, APYX stands at 179.6M. In comparison, MGRM has a market cap of 243.8M. Regarding current trading prices, APYX is priced at $4.29, while MGRM trades at $6.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
APYX currently has a P/E ratio of -19.50, whereas MGRM's P/E ratio is -11.11. In terms of profitability, APYX's ROE is -0.91%, compared to MGRM's ROE of -1.11%. Regarding short-term risk, APYX is more volatile compared to MGRM. This indicates potentially higher risk in terms of short-term price fluctuations for APYX.Check MGRM's competition here
APYX vs TMCI Comparison June 2026
APYX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, APYX stands at 179.6M. In comparison, TMCI has a market cap of 239.4M. Regarding current trading prices, APYX is priced at $4.29, while TMCI trades at $3.69.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
APYX currently has a P/E ratio of -19.50, whereas TMCI's P/E ratio is -3.84. In terms of profitability, APYX's ROE is -0.91%, compared to TMCI's ROE of -0.69%. Regarding short-term risk, APYX is more volatile compared to TMCI. This indicates potentially higher risk in terms of short-term price fluctuations for APYX.Check TMCI's competition here
APYX vs NVRO Comparison June 2026
APYX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, APYX stands at 179.6M. In comparison, NVRO has a market cap of 224.1M. Regarding current trading prices, APYX is priced at $4.29, while NVRO trades at $5.84.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
APYX currently has a P/E ratio of -19.50, whereas NVRO's P/E ratio is -1.91. In terms of profitability, APYX's ROE is -0.91%, compared to NVRO's ROE of -0.43%. Regarding short-term risk, APYX is more volatile compared to NVRO. This indicates potentially higher risk in terms of short-term price fluctuations for APYX.Check NVRO's competition here
APYX vs RXST Comparison June 2026
APYX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, APYX stands at 179.6M. In comparison, RXST has a market cap of 211.1M. Regarding current trading prices, APYX is priced at $4.29, while RXST trades at $5.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
APYX currently has a P/E ratio of -19.50, whereas RXST's P/E ratio is -4.51. In terms of profitability, APYX's ROE is -0.91%, compared to RXST's ROE of -0.17%. Regarding short-term risk, APYX is more volatile compared to RXST. This indicates potentially higher risk in terms of short-term price fluctuations for APYX.Check RXST's competition here
APYX vs EYES Comparison June 2026
APYX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, APYX stands at 179.6M. In comparison, EYES has a market cap of 210M. Regarding current trading prices, APYX is priced at $4.29, while EYES trades at $4.14.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
APYX currently has a P/E ratio of -19.50, whereas EYES's P/E ratio is N/A. In terms of profitability, APYX's ROE is -0.91%, compared to EYES's ROE of -2.64%. Regarding short-term risk, APYX is more volatile compared to EYES. This indicates potentially higher risk in terms of short-term price fluctuations for APYX.Check EYES's competition here
APYX vs PROF Comparison June 2026
APYX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, APYX stands at 179.6M. In comparison, PROF has a market cap of 205.8M. Regarding current trading prices, APYX is priced at $4.29, while PROF trades at $6.79.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
APYX currently has a P/E ratio of -19.50, whereas PROF's P/E ratio is -5.48. In terms of profitability, APYX's ROE is -0.91%, compared to PROF's ROE of -0.71%. Regarding short-term risk, APYX is more volatile compared to PROF. This indicates potentially higher risk in terms of short-term price fluctuations for APYX.Check PROF's competition here
APYX vs ANIK Comparison June 2026
APYX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, APYX stands at 179.6M. In comparison, ANIK has a market cap of 196.8M. Regarding current trading prices, APYX is priced at $4.29, while ANIK trades at $14.79.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
APYX currently has a P/E ratio of -19.50, whereas ANIK's P/E ratio is -18.72. In terms of profitability, APYX's ROE is -0.91%, compared to ANIK's ROE of -0.08%. Regarding short-term risk, APYX is more volatile compared to ANIK. This indicates potentially higher risk in terms of short-term price fluctuations for APYX.Check ANIK's competition here
APYX vs BSGM Comparison June 2026
APYX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, APYX stands at 179.6M. In comparison, BSGM has a market cap of 191.1M. Regarding current trading prices, APYX is priced at $4.29, while BSGM trades at $6.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
APYX currently has a P/E ratio of -19.50, whereas BSGM's P/E ratio is -5.81. In terms of profitability, APYX's ROE is -0.91%, compared to BSGM's ROE of +17.60%. Regarding short-term risk, APYX is less volatile compared to BSGM. This indicates potentially lower risk in terms of short-term price fluctuations for APYX.Check BSGM's competition here
APYX vs QTRX Comparison June 2026
APYX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, APYX stands at 179.6M. In comparison, QTRX has a market cap of 179M. Regarding current trading prices, APYX is priced at $4.29, while QTRX trades at $3.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
APYX currently has a P/E ratio of -19.50, whereas QTRX's P/E ratio is -1.62. In terms of profitability, APYX's ROE is -0.91%, compared to QTRX's ROE of -0.35%. Regarding short-term risk, APYX is less volatile compared to QTRX. This indicates potentially lower risk in terms of short-term price fluctuations for APYX.Check QTRX's competition here
APYX vs MDGS Comparison June 2026
APYX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, APYX stands at 179.6M. In comparison, MDGS has a market cap of 178.9M. Regarding current trading prices, APYX is priced at $4.29, while MDGS trades at $2.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
APYX currently has a P/E ratio of -19.50, whereas MDGS's P/E ratio is -0.27. In terms of profitability, APYX's ROE is -0.91%, compared to MDGS's ROE of -0.51%. Regarding short-term risk, APYX is less volatile compared to MDGS. This indicates potentially lower risk in terms of short-term price fluctuations for APYX.Check MDGS's competition here
APYX vs EDAP Comparison June 2026
APYX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, APYX stands at 179.6M. In comparison, EDAP has a market cap of 178.2M. Regarding current trading prices, APYX is priced at $4.29, while EDAP trades at $4.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
APYX currently has a P/E ratio of -19.50, whereas EDAP's P/E ratio is -5.80. In terms of profitability, APYX's ROE is -0.91%, compared to EDAP's ROE of -1.49%. Regarding short-term risk, APYX is more volatile compared to EDAP. This indicates potentially higher risk in terms of short-term price fluctuations for APYX.Check EDAP's competition here
APYX vs INGN Comparison June 2026
APYX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, APYX stands at 179.6M. In comparison, INGN has a market cap of 170.8M. Regarding current trading prices, APYX is priced at $4.29, while INGN trades at $6.31.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
APYX currently has a P/E ratio of -19.50, whereas INGN's P/E ratio is -6.93. In terms of profitability, APYX's ROE is -0.91%, compared to INGN's ROE of -0.13%. Regarding short-term risk, APYX is more volatile compared to INGN. This indicates potentially higher risk in terms of short-term price fluctuations for APYX.Check INGN's competition here
APYX vs QIPT Comparison June 2026
APYX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, APYX stands at 179.6M. In comparison, QIPT has a market cap of 162.3M. Regarding current trading prices, APYX is priced at $4.29, while QIPT trades at $3.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
APYX currently has a P/E ratio of -19.50, whereas QIPT's P/E ratio is -15.87. In terms of profitability, APYX's ROE is -0.91%, compared to QIPT's ROE of -0.10%. Regarding short-term risk, APYX is more volatile compared to QIPT. This indicates potentially higher risk in terms of short-term price fluctuations for APYX.Check QIPT's competition here
APYX vs CVRX Comparison June 2026
APYX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, APYX stands at 179.6M. In comparison, CVRX has a market cap of 156M. Regarding current trading prices, APYX is priced at $4.29, while CVRX trades at $5.88.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
APYX currently has a P/E ratio of -19.50, whereas CVRX's P/E ratio is -2.93. In terms of profitability, APYX's ROE is -0.91%, compared to CVRX's ROE of -1.21%. Regarding short-term risk, APYX is more volatile compared to CVRX. This indicates potentially higher risk in terms of short-term price fluctuations for APYX.Check CVRX's competition here
APYX vs NNOX Comparison June 2026
APYX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, APYX stands at 179.6M. In comparison, NNOX has a market cap of 144.1M. Regarding current trading prices, APYX is priced at $4.29, while NNOX trades at $2.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
APYX currently has a P/E ratio of -19.50, whereas NNOX's P/E ratio is -1.78. In terms of profitability, APYX's ROE is -0.91%, compared to NNOX's ROE of -0.47%. Regarding short-term risk, APYX is more volatile compared to NNOX. This indicates potentially higher risk in terms of short-term price fluctuations for APYX.Check NNOX's competition here
APYX vs SNWV Comparison June 2026
APYX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, APYX stands at 179.6M. In comparison, SNWV has a market cap of 135M. Regarding current trading prices, APYX is priced at $4.29, while SNWV trades at $15.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
APYX currently has a P/E ratio of -19.50, whereas SNWV's P/E ratio is 16.35. In terms of profitability, APYX's ROE is -0.91%, compared to SNWV's ROE of -4.51%. Regarding short-term risk, APYX is more volatile compared to SNWV. This indicates potentially higher risk in terms of short-term price fluctuations for APYX.Check SNWV's competition here